India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

Advances such as triple agonists, gene editing, and microbiome therapy offer hope for metabolic diseases, but global access and early detection remain limited.

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...

After months of deliberation, information gathering and testimony, a state board agreed Monday that two common medications ...

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

In a special raid conducted today, the Drugs Control Department seized a large cache of illegally stocked medicines valued at over ₹1.3 crore. The operation, carried out in the Paschim Vihar area, ...

The Department of Drugs Control, Delhi has seized unlicensed pharmaceutical stock worth more than Rs 1.3 crore from a residential apartment in Paschim Vihar, officials said on Tuesday. Delhi Health ...

The Delhi Drugs Control Department on Tuesday seized unlicensed medicines worth over Rs 1.3 crore from a flat in Paschim ...

The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.